Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation
Generalized pustular psoriasis (GPP) is a serious, immune-mediated inflammatory skin disease with significant morbidity and mortality. Estimates of GPP prevalence vary between 1.8 and 124 per million people.1 GPP pathogenesis primarily involves abnormal activation of the interleukin (IL)-36 pathway of the innate immune system, with secondary contributions from the adaptive immune system. Through a validated Delphi method,2,3 32 physicians specializing in psoriatic diseases from the Medical Board of the National Psoriasis Foundation formulated the following consensus statements to guide clinicians, payors, and patients in GPP management.